ERIS LIFESCIENCES LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 980.4 INR | +0.27% |
|
+7.08% | +7.80% |
| May. 22 | Eris Lifesciences Posts Gains in Fiscal Q4 Consolidated Net Profit | MT |
| May. 21 | Eris Lifesciences Gets Board Nod to Raise Up to INR12.50 Billion Via Bond Sale | MT |
| Sales 2024 | 20.09B 241M | Sales 2025 * | 29.74B 357M | Capitalization | 133B 1.59B |
|---|---|---|---|---|---|
| Net income 2024 | 3.92B 46.99M | Net income 2025 * | 4.08B 48.84M | EV / Sales 2024 | 6.37 x |
| Net Debt 2024 | 13.35B 160M | Net Debt 2025 * | 25.31B 303M | EV / Sales 2025 * | 5.32 x |
| P/E ratio 2024 |
29.3
x | P/E ratio 2025 * |
33.1
x | Employees | 3,548 |
| Yield 2024 * |
0.73% | Yield 2025 * |
0.71% | Free-Float | 26.51% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eris Lifesciences Limited
| 1 day | +6.60% | ||
| 1 week | +7.10% | ||
| Current month | +6.74% | ||
| 1 month | +12.24% | ||
| 3 months | +9.27% | ||
| 6 months | +7.20% | ||
| Current year | +7.46% |
1 week
815.85
992.25
1 month
815.85992.25
Current year
809.15992.25
1 year
640.00992.25
3 years
551.30992.25
5 years
321.00992.25
10 years
321.00992.25
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 07-01-26 | |
Vijay S. Joshi
PSD | President | - | 10-04-30 |
Sachin Shah
DFI | Director of Finance/CFO | 44 | 12-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kalpana Unadkat
BRD | Director/Board Member | 53 | 21-01-04 |
Prashant Gupta
BRD | Director/Board Member | 44 | 18-04-29 |
| Chief Executive Officer | 50 | 07-01-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 112 M€ | +4.86% | - | |
| 0.00% | 45 M€ | 0.00% | - | |
| 0.00% | 7 M€ | +6.43% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 980.4 | +0.27% | 333 549 |
| 24-06-06 | 977.8 | +6.60% | 768,455 |
| 24-06-05 | 917.4 | +0.76% | 208,042 |
| 24-06-04 | 910.4 | -0.47% | 161,244 |
| 24-06-03 | 914.8 | -0.15% | 66,221 |
Delayed Quote NSE India S.E., June 06, 2024 at 07:43 am EDT
More quotes
Eris Lifesciences Limited is an India-based company that is primarily engaged in the manufacturing and marketing of pharmaceutical products. The Companyâs manufacturing plant is located in Guwahati, Assam. Its therapeutic areas include oral diabetes care, cardiac care, pain/analgesics, gynecology, gastrointestinal, central nervous system (CNS), and vitamins, minerals, and nutrients (VMN). The Company's brands include Advog 0.2, Atorsave Gold 10, Baga NT 100, Calshine 60K Tablet, Carpela, Cilentra Plus 5, Cognix, D1000cal, Enoxsave 60, Glimisave M 4 forte, Levroxa 1000, Mac Rabonik Plus, Glimisave, Eritel, Renerve, Tendia, Olmin, Rabonik, Tayo, Cyblex, Lnbloc, Remylin, Zomelis, Crevast, Atorsave, Ginkocer and Metital. The Companyâs wholly owned subsidiaries include Kinedex Healthcare Private Limited, Aprica Healthcare Limited, and Eris Healthcare Private Limited.
Sector
Pharmaceuticals
Calendar
2024-07-25
- Q1 2025 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
977.8
INR
Average target price
1,092
INR
Spread / Average Target
+11.64%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +7.46% | 1.5B | |
| +43.64% | 749B | |
| +39.42% | 605B | |
| -6.58% | 351B | |
| +19.72% | 328B | |
| +8.78% | 292B | |
| +11.92% | 216B | |
| -2.62% | 214B | |
| +0.03% | 167B | |
| +6.13% | 165B |
- Stock Market
- Equities
- ERIS Stock
